Clinical Trials

Developing the future fight against cancer

We’re proud to be participating in world-leading clinical trials that provide breakthrough treatments for cancer.

Running these trials means we can get our patients access to cutting-edge medicines and cancer treatments that would otherwise not be accessible in New Zealand.

All participants in cancer treatment trials contribute to the collective research effort aimed at developing treatments that will ultimately save lives.

FOR PATIENTS

If you would like to discuss if one of our trials is right for you, please speak with your treating medical team to arrange a referral. We can not take self-referrals.

FOR CLINICIANS

If referring a patient for participation in a clinical trial, please send a referral letter, including medical history, histopathology and molecular pathology results, to referrals@harbourcancer.co.nz

CLINICAL TRIALS BROCHURE

Download the brochure here to find out more about clinical trials.

CLINICAL TRIAL TYPES & PHASES

You may have noticed a change in our name recently, to Harbour Cancer & Wellness. Our vision is to provide cutting-edge treatments within a holistic and integrated model of cancer care.

In this update, we want to tell you more about our integrated Wellness services, introduce some new people in our team, and also share

READ MORE




CURRENT CLINICAL TRIALS

Keyvibe-10

The purpose of this study is to learn if vibostolimab, a new type of immunotherapy, with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if pembrolizumab with vibostolimab is better than receiving pembrolizumab alone at preventing the melanoma from returning.

Diagnosis: Melanoma
Stage: II/III/IV fully resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05665595

V940-007

A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC).

This is a two-part (Phase 2/Phase 3) study of V940, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms V940 plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that V940 plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to V940 plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrolment or study endpoints.

Diagnosis: Squamous Cell Carcinoma
Stage: Locally advanced, resectable
Setting: Neoadjuvant/Adjuvant
Status: In Start-Up
Trial ID: NCT06295809

Keyvibe-010

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010).

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.

Diagnosis: Melanoma
Stage: II/III/IV fully resected
Setting: Adjuvant
Status: Recruitment closed
Trial ID: NCT05665595

V940-001

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma.

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

Diagnosis: Melanoma
Stage: II/III/IV fully resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05933577

V940-002

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer.

The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.

Diagnosis: NSCLC
Stage: II/IIIA/IIIB resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT06077760

STAY IN TOUCH

If you would like to get in contact with us and discuss any of our services further please feel free to contact us on 09 220 3333 or email us at reception@harbourcancer.co.nz / wellness@harbour.co.nz

We look forward to hearing from you.

View Our Locations